ViroCell strengthens senior management team with appointment of Nick Maishman as COO

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (“COO”).

ViroCell, an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”), is today addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

In the NewsFlorence BuchananNovember 22, 2022viral vectors, UK CDMO, CDMO, gene therapy, cell therapy, clinical trials, cell and gene therapies, Nick Maishman, ViroCell, Pharmiweb.com

ViroCell Strengthens Senior Management Team with Appointment of Nick Maishman as COO

ViroCell Biologics, founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (COO).

ViroCell, an innovation-driven Contract Development and Manufacturing Organisation, is today addressing the global viral vector supply-demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene-modified cells for clinical trials. ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.

In the NewsFlorence BuchananNovember 22, 2022UK CDMO, CDMO, gene therapy, cell therapy, cell and gene therapies, clinical trials, Nick Maishman, Pharmtech Focus, viral vectors

ViroCell names Susan Nichols as CBO

ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO).

The firm is seeking to address the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies by focussing on the design and GMP manufacture of viral vectors…

In the NewsFlorence BuchananSeptember 20, 2022UK CDMO, CDMO, gene therapy, cell therapy, cell and gene therapies, clinical trials, viral vectors, Susan B Nichols, ViroCell, The Pharma Letter

ViroCell Announces the Appointment of Susan B. Nichols as CBO

ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.

In the NewsFlorence BuchananSeptember 20, 2022UK CDMO, gene therapy, cell therapy, ViroCell, Pharmtech Focus, clinical trials, cell and gene therapies, CDMO, Susan B Nichols, viral vectors

Tech News: ViroCell Biologics

ViroCell Biologics, the UK’s first clinical trial-focused viral vector manufacturer, has officially launched.

It aims to be the supplier of choice for viral vectors and gene-modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

In the NewsFlorence BuchananJune 3, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, The Biomedical Scientist, vector design, gene therapy, cell therapy, CGT, UK CDMO, Farzin Farzaneh, King's College London, viral vector

ViroCell - the UK’s First Clinical Trial Focused Viral Vector Manufacturer

ViroCell Biologics,

In the NewsFlorence BuchananMay 12, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, Rapid Virology, UK CDMO, vector design, gene therapy, cell therapy, AAV vectors, lentivirus vectors

Viral Vectors And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type (AAV, Lentivirus)...

The global viral vectors and plasmid DNA manufacturing market size was valued at USD 2.87 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 14.71% from 2022 to 2030.

In the NewsFlorence BuchananMay 5, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, UK CDMO, gene therapy, cell therapy

First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies

ViroCell released in the UK to make viral vectors

ViroCell will supply viral vectors and genetically modified cells to academic and corporate customers for translational cell and gene therapy entering clinical trials.

Global Roundup. Elsewhere across the globe: ViroCell Biologics

ViroCell Biologics – U.K.-based ViroCell launched with the goal to become the supplier of choice for viral vectors and gene-modified cells. Viral vectors are the primary delivery method for many innovative vaccines.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, BioSpace, UK CDMO, ViroCell, gene therapy, cell therapy, viral vector, vector design, AAV vectors, lentivirus vectors, Farzin Farzaneh

First UK-based clinical trial manufacturer focused on viral vectors announces launch

ViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, CCR, Complete Clinical Research, gene therapy, cell therapy, vector design, AAV vectors, lentivirus vectors, UK CDMO, ViroCell, Edi Truell

ViroCell Launched in the UK to Manufacture Viral Vectors

ViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, PharmTech.com, gene therapy, cell therapy, AAV vectors, lentivirus vectors, UK CDMO, Farzin Farzaneh, Truell Conservation Foundation, Edmund Truell, King's College London, vector design, CGT

First UK-based clinical trial focused viral vector manufacturer announces launch...

ViroCell Biologics, the first clinical trial focused viral vector manufacturer in the UK, has announced its official launch, with the aim of becoming the ‘supplier of choice’ for viral vectors and gene modified cells.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, PharmaTimes, vector design, AAV vectors, lentivirus vectors, UK CDMO, CGT, gene therapy, cell therapy, Truell Conservation Foundation

First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the primary clinical trial focused viral vector manufacturer within the UK, has introduced its official launch, with the intention of turning into the ‘supplier of choice’ for viral vectors and gene modified cells.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, ViroCell, Farzin Farzaneh, Truell Conservation Foundation, John Hadden II, gene therapy, cell therapy, CGT, UK CDMO, UR ALL news, vector design, AAV vectors, lentivirus vectors

Introducing ViroCell Biologics

In the NewsFlorence BuchananApril 28, 2021CDMO, clinical trials, viral vectors, cell and gene therapies

In the news

London New York